# Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors

Source: https://onco.cc/trials/nct07512583/  
OnCo record `nct07512583` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of TQB2102 and TQB2930 in advanced solid tumours, run by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., now recruiting.

## Summary

Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07512583 by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., with 178 participants planned, started 2026-05-27 and due to reach its primary completion in 2028-03. Interventions recorded: TQB2930 injection+TQB2102 for injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07512583
- Phase: 1/2
- Setting: Phase Ib/II Clinical Trial of TQB2930 Injection in Combination With TQB2102 for Injection in Patients With HER2-Expressing Advanced Solid Tumors
- Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Enrolled: 178

## Sources

- ClinicalTrials.gov NCT07512583: https://clinicaltrials.gov/study/NCT07512583

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [TQB2102](https://onco.cc/drugs/tqb2102/), [TQB2930](https://onco.cc/drugs/tqb2930/)
- companies: [Sino Biopharmaceutical (Chia Tai Tianqing)](https://onco.cc/companies/sino-biopharm/)

---
JSON: https://onco.cc/api/v1/entities/nct07512583.json